Project Grant RF1AG094856
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- The University of South Florida received a $3,385,215 Project Grant award from the National Institute on Aging, part of the National Institutes of Health within the Department of Health and Human Services. The grant was awarded under the Aging Research program (CFDA 93.866) to fund research titled "Microbial Therapy Improves Gut Permeability to Reduce Cognitive Decline and Alzheimer's Disease." The grant will support research from August 2021 through July 2024 to study the impact of...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $848,286 to the University of South Florida to conduct research on the role of N6-methyladenosine (m6A) RNA modifications in Alzheimer's disease (AD). The key objectives are to: 1) Create a high-resolution map of m6A sites in the brains of older adults, 2) Identify specific m6A alterations associated with AD and its clinical/pathological features, and 3) Elucidate how m6A dysregulation may...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $412,500 Project Grant to the University of South Florida to investigate changes in the brain extracellular matrix during normal aging and in Alzheimer's disease. The 2-year grant, which runs from Jun 1, 2025 to May 31, 2027, aims to establish region-specific extracellular matrix composition in mouse brains, elucidate changes during normal aging, and characterize temporal and spatial...
- The University of Florida was awarded a $507,371 project grant from the National Institute on Aging under the Aging Research federal grant program (CFDA 93.866) to study the roles of CASP8 GGGAGA repeat expansions in Alzheimer's disease. The project aims to investigate a novel genetic variant associated with increased Alzheimer's disease risk, with a focus on the molecular mechanisms by which this repeat expansion may contribute to the development of the disease. The project period runs from...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $445,625 to Rutgers, The State University to develop an innovative nanotechnology approach to interrupt amyloid-beta (Aβ) aggregation and attenuate neuroinflammation in Alzheimer's disease (AD). The key objectives are to: (1) elucidate how scavenger receptor-targeted nanoparticles can ameliorate Aβ-mediated pathological glial communications, and (2) evaluate the longer-term neuroprotective...
- The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...